

Materials for this course will release 04/13/2022

Pharmacotherapy Specialty Recertification Literature Study: Module 1A-C (Cert # L229101)

Teaser: The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Tag: Certifications; Pharmacotherapy



ACPE Numbers: Various – see listing below

Pre-Sale Date: 03/16/2022

Content Release Date: 04/13/2022

Expiration Dates: 10/18/2022

Activity Type: Application-based

CE Credits: 15 contact hours

Activity Fee: \$55 (ASHP member); \$110 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding.

Module 1A – Medication Safety and Statistics: This module focuses on medication safety issues and research evaluation.

Module 1B – Infectious Diseases: This module focuses on current issues in infectious diseases including updated guidelines, reviews, and clinical trials.

Module 1C – Pediatrics, Pain, and Neurology: This module focuses on pediatrics, pain management, and the treatment and prevention of ischemic stroke.

Materials for this course will release 04/13/2022

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 15 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Pharmacotherapy and Critical Care Literature Study Module 1A: Medication Safety and Statistics	0204-0000-22-932-H01-P	5.0	TBD
Pharmacotherapy Literature Study Module 1B: Infectious Diseases	0204-0000-22-933-H01-P	5.0	TBD
Pharmacotherapy Literature Study Module 1C: Pediatrics, Pain, and Neurology	0204-0000-22-934-H01-P	5.0	TBD
Recertification Assessment Group 1		15.0 BPS	

Module 1A: Medication Safety and Statistics

ACPE Number: 0204-0000-22-932-H01-P

Owen VS, Rosgen BK, Cherak SJ et al. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis. *Crit Care*. 2021; 25:146.

Learning Objectives:

- Describe the systematic review and meta-analysis by Owen and colleagues of studies of the administration of vasopressor medications through a peripheral intravenous (PIV) catheter.
- Develop recommendations for the route of administration of vasopressor medications.

Nazer LH, Brown ART, Awad W. Iatrogenic toxicities in the intensive care unit. *Critical Care Clinics*. 2021; 37 (3): 625 - 641.

Learning Objectives:

- Describe the mechanisms, clinical presentation, diagnosis, and management of iatrogenic toxicities associated with medications commonly used in the intensive care unit (ICU).
- Develop recommendations for the management of iatrogenic toxicities associated with medications commonly used in the intensive care unit (ICU).

Materials for this course will release 04/13/2022

Kane-Gill SL. Nephrotoxin stewardship. *Critical Care Clinics* 2021; 37: 303-320.

Learning Objectives:

- Define nephrotoxin stewardship and describe its goals and the approaches used to achieve them.
- Develop recommendations for nephrotoxin stewardship to improve medication safety, ensure kidney health, and minimize unnecessary costs for medical tests and treatments for critically-ill patients.

Kollef MH, Torres A, Shorr AF et al. Nosocomial infection. *Crit Care Med.* 2021; 49: 169-187.

Learning Objectives:

- Describe trends in nosocomial infections (NIs) in the intensive care unit (ICU) setting, the roles of the host-microbiome interaction and antimicrobial resistance, and strategies for the treatment and prevention of these infections.
- Develop recommendations for the management of nosocomial infections (NIs) in patients in the intensive care unit (ICU).

Afanasjeva J, Burk M, Cunningham FF, et al. ASHP Guidelines on Medication-Use Evaluation. *Am J Health Syst Pharm.* 2021; 78(2): 168-175. <https://pubmed.ncbi.nlm.nih.gov/33399190/>.

Learning Objectives:

- Describe the 2021 ASHP guidelines on medication-use evaluation (MUE), including goals and objectives, performance improvement methods, indicators suggesting a need for MUE, prioritization of medications and processes for evaluation, typical steps in the process, roles and responsibilities of the interdisciplinary team, and common problems and pitfalls.
- Develop recommendations for medication-use evaluations (MUEs), including goals, methods, roles and responsibilities of team members, indicators of the need for MUE, and common pitfalls.

Gershon AS, et al. Informing healthcare decisions with observational research assessing causal effect: An official American Thoracic Society Research Statement. *Am J Resp and Crit Care Med.* 2020; 203(1): 14-23.

Learning Objectives:

- Describe the American Thoracic Society (ATS) research statement on making healthcare decisions and establishing clinical practice guidelines and healthcare policies for critically ill patients based on findings from observational studies of the causal effect of an intervention on outcomes
- Develop recommendations for the use of findings from observational studies of the causal effect of an intervention on outcomes in establishing clinical practice guidelines and healthcare policies and making healthcare decisions for critically ill patients.

Abrams D, Montesi S, Moore SKL et al. Powering bias and clinically important treatment effects in randomized trials of critical illness. *Crit Care Med.* 2020; 48: 1710-1719.

Learning Objectives:

- Describe the study by Abrams and colleagues of powering bias and clinically important treatment effects in multicenter randomized controlled trials (RCTs) of critically ill adults.
- Develop recommendations for the design of multicenter randomized controlled trials (RCTs) of critically ill adults.

Materials for this course will release 04/13/2022

Module 1B: Infectious Diseases

ACPE Number: 0204-0000-22-933-H01-P

Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. *Clin Inf Dis*. 2021; 73:e1029-e1044.

Learning Objectives:

- Describe the clinical practice guideline with a 2021 focused update from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) on the management of Clostridioides difficile infection (CDI) in adults.
- Develop recommendations for the management of Clostridioides difficile infection (CDI) in adults based on the 2021 focused update from IDSA and SHEA.

Saag MS. HIV Infection - screening, diagnosis, and treatment. *N Engl J Med*. 2021; 384: 2131-2143.

Learning Objectives:

- Describe the screening, diagnosis, and treatment of HIV infection.
- Develop recommendations for the screening, diagnosis, and treatment of HIV infection.

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). *Clin Infect Dis*, 2021;72(7):1109-1116.

Learning Objectives:

- Describe the Infectious Diseases Society of America (IDSA) guidance on the treatment of extended-spectrum β -lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
- Develop recommendations for the treatment of extended-spectrum β -lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).

Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. *MMWR*. 2021;70(4):1-192.

(IMPORTANT: For this Literature Study, only pages 65-80 (chlamydia and gonorrhea) are assessed.)

Learning Objectives:

- Describe the 2021 Centers for Disease Control and Prevention (CDC) treatment guidelines for sexually transmitted infections involving Chlamydia trachomatis and Neisseria gonorrhoeae.
- Develop recommendations for screening for and treating chlamydial and gonococcal infections.

Materials for this course will release 04/13/2022

Bernard L, Arvieux C, Brunschweiler B et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. *N Engl J Med.* 2021; 384:1991-2001.

Learning Objectives:

- Describe the Duration of Antibiotic Treatment in Prosthetic Joint Infection (DATIPO) study by Bernard and colleagues.
- Develop recommendations for antibiotic therapy for patients with microbiologically confirmed prosthetic joint infections managed with standard surgical procedures.

Sutton JD, Steven VW, Chang NC et al. Oral β -lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of Enterobacterales bacteremia from a urine source. *JAMA Netw Open.* 2020; 3(10):e2020166.

(IMPORTANT: Information contained in the Supplement is also assessed.)

Learning Objectives:

- Describe the study by Sutton and colleagues comparing oral β -lactam antibiotics with a fluoroquinolone or trimethoprim-sulfamethoxazole for the treatment of Enterobacterales bacteremia with a suspected urinary source.
- Develop recommendations for the treatment of adults with Enterobacterales bacteremia with a suspected urinary source.

Module 1C: Pediatrics, Pain, and Neurology

ACPE Number: 0204-0000-22-934-H01-P

Kelley-Quon LI, et al. Guidelines for opioid prescribing in children and adolescents after surgery: An expert panel opinion. *JAMA Surg.* 2021; 156: 76-90.

Learning Objectives:

- Describe the guidelines from Kelley-Quon and colleagues for opioid prescribing in children and adolescents after surgery.
- Develop recommendations for perioperative and postoperative opioid use in children and adolescents.

Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW, Kutlar A, Seisa M, Stinson J, Strouse JJ, Yusuf F, Zempsky W, Lang E. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv.* (2020) 4 (12): 2656–2701.

<https://doi.org/10.1182/bloodadvances.2020001851>

Learning Objectives:

- Describe the American Society of Hematology (ASH) 2020 guidelines for the management of acute and chronic pain in patients with sickle cell disease (SCD).
- Develop recommendations for managing acute and chronic pain in patients with sickle cell disease (SCD).
- Identify limitations to the current ASH guidelines and opportunities for future research.

Materials for this course will release 04/13/2022

Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021; 52:e364-e467.

Learning Objectives:

- Describe the 2021 guideline from the American Heart Association (AHA) and American Stroke Association (ASA) for the secondary prevention of stroke in patients with stroke or transient ischemic attack (TIA).
- Develop recommendations for the secondary prevention of stroke in patients with ischemic stroke or transient ischemic attack (TIA).

Herpich F, Rincon F. Management of Acute Ischemic Stroke. *Crit Care Med*. 2020; 48 (11): 1654-1663.

Learning Objectives:

- Describe the management of acute ischemic stroke (AIS), including early detection, prehospital and emergency management, neuroimaging, revascularization, management in the intensive care unit (oxygen, ventilation, blood pressure, glucose, cerebral edema, fever), rehabilitation, nutrition, and secondary prevention through risk factor modification.
- Develop recommendations for the management of acute ischemic stroke.

Zhong CS, Beharry J, Salazar D, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. *Stroke* 2021; 52: 1087-1090.

Learning Objectives:

- Describe the study by Zhong and colleagues of tenecteplase for thrombolysis in patients with acute ischemic stroke.
- Develop recommendations for thrombolytic therapy in patients with acute ischemic stroke.

Faculty

Samuel L. Aitken, Pharm.D., M.P.H., BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dana R. Bowers, Pharm.D., BCIDP, BCPS (AQ-ID)
Clinical Assistant Professor
Washington State University
College of Pharmacy and Pharmaceutical Sciences
Yakima, Washington

Meagan Adamsick, Pharm.D., BCIDP
Clinical Pharmacy Specialist
Massachusetts General Hospital
Boston, Massachusetts

Christopher Carter, Pharm.D., BCCCP, FCCM
Clinical Manager - Pharmacy Services
SSM Health St. Clare Hospital – Fenton
Fenton, Missouri

Monique Bidell, Pharm.D., BCPS
Infectious Diseases Clinical Pharmacist
Massachusetts General Hospital
Boston, Massachusetts

Brooklyn Cobb, Pharm.D., BCPS
Clinical Pharmacy Specialist, Ambulatory Care
Memorial Hermann Southwest Hospital
Houston, Texas

Materials for this course will release 04/13/2022

Brian Dee, Pharm.D., BCCCP, BCNSP, FCCM
Clinical Pharmacy Specialist - Critical Care/Nutrition
Support
The University of Texas MD Anderson Cancer Center
Houston, Texas

Julie Harting, Pharm.D., BCIDP
Associate Professor / Clinical Pharmacist Specialist,
Infectious Disease
Sullivan University College of Pharmacy and Health
Sciences / University of Louisville Hospital
Louisville, Kentucky

Lauren Igneri, Pharm.D., BCPS, BCCCP
Clinical Pharmacy Specialist, Critical Care
Cooper University HealthCare
Camden, New Jersey

Bryan Lizza, Pharm.D., M.S., BCCCP
Clinical Specialist - Medicine Critical Care
Barnes Jewish Hospital
St Louis, Missouri

Lindsay McCann, Pharm.D., BCCCP
Critical Care Clinical Pharmacy Specialist
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania

Lane Nguyen, Pharm.D., BCPPS
Clinical Pharmacy Specialist
Pediatric Critical Care Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Neha Sheth Pandit, Pharm.D., BCPS, AAHIVP
Associate Professor
University of Maryland
School of Pharmacy
Baltimore, Maryland

Ashley Sabus, Pharm.D., BCOP
Clinical Pharmacy Specialist - Pediatric
Oncology/Bone Marrow Transplant
Texas Children's Hospital
Houston, Texas

Rachel Swope, Pharm.D., BCCCP
Clinical Pharmacy Manager
Norton Healthcare
Louisville, Kentucky

Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSH
Professor, Department of Clinical and
Administrative Sciences
Sullivan University College of Pharmacy
Cardiology Clinical Pharmacy Specialist
Jewish Hospital Rudd Heart and Lung Center
Louisville, Kentucky

Snehal Bhatt, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health
Science
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Angela Bingham, Pharm.D., BCPS, BCNSP, BCCCP,
FASPEN, FCCP
Interim Vice Chair and Associate Professor of
Clinical Pharmacy, PGY2 Critical Care Pharmacy
Residency Program Director, Residency Programs
Coordinator
Philadelphia College of Pharmacy, University of the
Sciences
Philadelphia, Pennsylvania
Critical Care Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey

Materials for this course will release 04/13/2022

Kevin W. Garey, Pharm.D., M.S., FASHP, FIDSA
Professor and Chair
University of Houston
Houston, Texas

Mary M. Hess, Pharm.D., FASHP, FCCM, FCCP,
BCCCP
Associate Dean
Professor, Pharmacy Practice
Jefferson College of Pharmacy
Philadelphia, Pennsylvania

Jason J. Schafer, Pharm.D., M.P.H., BCPS, BCIDP,
AAHIVP, FASHP
Professor and Vice Chair, Department of Pharmacy
Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Douglas Slain, Pharm.D., BCPS, AQ-ID
Professor & Infectious Diseases Clinical Specialist
West Virginia University
Morgantown, West Virginia

Kayla R. Stover, Pharm.D., BCPS, BCIDP, FCCP, FIDSA
Associate Professor
University of Mississippi School of Pharmacy
Madison, Mississippi

Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP,
FCCM
Director of Clinical Pharmacy
Brigham & Women's Hospital
Boston, Massachusetts

Evan Zasowski, Pharm.D., M.P.H., BCPS, BCIDP
Assistant Professor, Department of Clinical Sciences
Touro University California College of Pharmacy
Vallejo, California

Reviewers

Susan R. Dombrowski, M.S., R.Ph.
Anna M. Wodlinger-Jackson, Pharm.D., BCPS

Field Testers

Jennifer Adema, Pharm.D., MBA, BCPS
Dawn Anderson, Pharm.D., MBA, BCPS
Angela Antonello, Pharm.D., BCPS
John Austin, Pharm.D., BCPS, BCCCP
Carrie Baker, Pharm.D., MBA, BCPS
Mary Grace Bouldin, Pharm.D., BCPS
Quintin Broussard, Pharm.D., BCPS, BCCCP, BCNSP
Jennifer Catlin, Pharm.D., BCPS, BCCCP
Sara Davis, Pharm.D., BCPS
Shannon Eidsness, Pharm.D., BCPS
Michelle Fang, Pharm.D., BCPS
Stefanie Forman, Pharm.D., BCPS, BCCCP
Lauren Giblin, Pharm.D., BCPS
Carmen Gust, Pharm.D., BCPS
Julie Haase, Pharm.D., BCPS, BCCCP
Brianna Hansen, Pharm.D., BCPS, BCCCP
Kiah Hicks, Pharm.D., BCPS
Laura Hicks, R.Ph., BCPS
Diem Ho, Pharm.D., BCPS

Raquel Jones, Pharm.D., BCPS
Jacky Lee, Pharm.D., BCPS, BCCCP
Isaiah Liebel, Pharm.D., BCPS
Kimberley Limouze, Pharm.D., BCPS, BCCCP
Melanie Madorsky, Pharm.D., BCPS, BCCP, BCCCP
Claudia Martin Diaz, Pharm.D., BCPS, BCOP
Kathryn McCanna, Pharm.D., BCPS
Sarah Miller, Pharm.D., BCPS
Oussayma Moukhachen, Pharm.D., BCPS, BCCCP
Madeline Ott, Pharm.D., BCPS
Kalindi Patel, Pharm.D., BCPS
Cara Phillips, Pharm.D., BCPS, BCCCP
Rebecca Powell, Pharm.D., BCPS
Kaitlin Pruskowski, Pharm.D., BCPS, BCCCP, FCCM
Hugh Quinn, Pharm.D., BCPS
Katy Rolfes, Pharm.D., BCPS, BCCCP
Nahirony Sanchez, Pharm.D., BCPS, BCGP
Nicholas Scarpino, Pharm.D., BCPS
Bridger Singer, Pharm.D., BCPS, BCCCP

Materials for this course will release 04/13/2022

Donald Singh, Pharm.D., MBA, BCPS
Katherine Taylor, Pharm.D., BCPS
Jonathan Tiongson, Pharm.D., BCPS
Jordan Todd, Pharm.D., BCPS
Emily Valentine, Pharm.D., BCPS

Barbara Wiggins, Pharm.D., BCPS, BCCP, BCCCP
Michael Wysong, Pharm.D., BCPS
Cathy Young, Pharm.D., BCPS, NCPS

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Snehal Bhatt: Speakers Bureau, Janssen Pharmaceuticals, Inc.

All other planners, presenters, reviewers, ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ASHP.
